| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer
1 company
Cittadine Andrew is a Chief Operating Officer at Monopar Therapeutics. Recent SEC Form 4 filings include 12 buys and 0 sells.
Estimated insider holdings value: $3.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 20, 2024 | MNPR Monopar Therapeutics | Chief Operating Officer | Buy | 32,508 | $0.79 | $25,573.85 | +10.2% | +17.1% | +876.5% | |
| Jun 17, 2024 | MNPR Monopar Therapeutics | Chief Operating Officer | Buy | 36,000 | $0.91 | $32,894.40 | +9.3% | -2.6% | +693.0% | |
| Jun 4, 2024 | MNPR Monopar Therapeutics | Chief Operating Officer | Buy | 24,000 | $0.77 | $18,480.00 | +12.0% | -38.4% | +825.7% | |
| May 31, 2024 | MNPR Monopar Therapeutics | Chief Operating Officer | Buy | 36,000 | $0.64 | $23,050.80 | +17.2% | -22.4% | +938.5% | |
| Nov 15, 2022 | MNPR Monopar Therapeutics | Chief Operating Officer | Buy | 16,053 | $3.09 | $49,659.00 | +71.6% | +30.2% | -88.1% |